Emerging Role of Rexinoids in Non-Small Cell Lung Cancer: Focus on Bexarotene

Emerging Role of Rexinoids in Non-Small Cell Lung Cancer: Focus on Bexarotene James R. Rigas, Konstantin H. Dragnev Oncologist 2005; 10: 22-33 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Explain the role of retinoids in cell division, growth, differentiation, and proliferation. Discuss the phase I, II, and III data using rexinoids to extend survival in NSCLC patients. Describe the expected toxicity profile of retinoids and rexinoids. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jan. 04, 2005 Most Recent Review: Jan. 04, 2005* Most Recent Update: Jan. 04, 2005 Date Credit Expires: Apr. 12, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.